Biolife Solutions (BLFS) EBIT (2010 - 2026)

Biolife Solutions (BLFS) has 17 years of EBIT data on file, last reported at $27000.0 in Q1 2026.

• On a quarterly basis, EBIT rose 105.41% year-over-year to $27000.0 in Q1 2026; TTM through Mar 2026 was -$15.4 million, a 813.62% decrease from a year earlier, with the FY2025 full-year figure at -$16.6 million, down 270.83% from the prior year.
• EBIT for Q1 2026 stood at $27000.0, down from $1.3 million in the prior quarter.
• Over the last five years, EBIT for BLFS reached as high as $90.3 million in Q4 2022 and fell as low as -$76.6 million in Q2 2022.
• Historically, EBIT has averaged -$2.8 million across 5 years, with a median of -$1.3 million in 2024.
• On a YoY basis, EBIT climbed as much as 589.29% in 2022 and fell as far as 1580.86% in 2022.
• Year by year, EBIT stood at $90.3 million in 2022, then sank by 80.6% to $17.5 million in 2023, then plunged by 96.91% to $542000.0 in 2024, then surged by 148.52% to $1.3 million in 2025, then sank by 98.0% to $27000.0 in 2026.
• Per Business Quant data, the three most recent EBIT figures were $27000.0 in Q1 2026, $1.3 million in Q4 2025, and -$89000.0 in Q3 2025.